Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

Shire teams up with Microsoft and EURORDIS for rare disease project

Will work to accelerate the time to diagnosis for children

- PMLiVE

mXm Group bolsters its editorial and account handing teams

New joiners include Chris Watson, Tony Cornell and Sunita Ram

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

- PMLiVE

Ten years at the forefront of patient experience

This month marks ten years of Hive, which has prompted us to reflect on how the world has changed over the last decade, and how it is going to change...

- PMLiVE

Big data, privacy and the rise of genomic testing

Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Blue Latitude Health

Deal Watch January 2018

One key question for 2018 is whether the recent US tax changes will have an effect on M&A in our industry - time will tell.  The year opened with a small...

Traditional vs Flipped

Emotional Intelligence and Blended Learning in Healthcare

EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action.

Cuttsy + Cuttsy

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

AstraZeneca AZ

AZ bags key lung cancer approval for Imfinzi

Becomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

- PMLiVE

A marathon and a sprint

Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links